We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Gene Panel May Be Able to Identify Existing and Potential Alcoholics

By LabMedica International staff writers
Posted on 02 Jun 2014
A Convergent Functional Genomics (CFG) approach was used to discover genes involved in alcoholism in a study that has implications for genetic testing to assess risk for developing an illness before the illness manifests itself clinically.

The CFG technique was developed by Dr. More...
Alexander Niculescu of the Indiana University School of Medicine (Indianapolis, USA), and collaborators starting in 1999. It is an approach for identifying and prioritizing candidate genes and biomarkers for complex psychiatric and medical disorders by integrating and tabulating multiple lines of evidence including gene expression and genetic data from human studies and from animal model work. CFG generates a signal that is predictive and is reproducible in independent studies, as opposed to the fit-to-cohort aspect of classic human genetic studies like the genome-wide association study (GWAS), where the issue of genetic heterogeneity makes the top statistically significant findings from even large size studies less reproducible in independent studies.

In the current work, Dr. Niculescu and collaborators in the United States and Germany used CFG to analyze data from a German genome-wide study of alcoholism and data from a variety of other studies into genetic links to alcoholism. The analysis produced a group of 135 candidate genes. They then used a stress-reactive animal model of alcoholism, the D-box binding protein (DBP) knockout mouse, to identify genes expressed by both the alcoholic humans and the stress-reactive alcoholic mice.

This process yielded a panel of 11 genes with 66 single-nucleotide polymorphisms (SNPs). The investigators found that this panel of 11 genes could be used to differentiate between alcoholics and non-alcoholics in three different research populations for which genetic data and information about alcohol consumption were available: a group of Caucasian subjects and a group of African American subjects from the USA, and a third group from Germany.

"This powerful panel of just 11 genes successfully identified who has problems with alcohol abuse and who does not in tests in three patient populations on two continents, in two ethnicities and in both genders," said senior author Dr. Alexander B. Niculescu, associate professor of psychiatry and medical neuroscience at the Indiana University School of Medicine. "We believe this is the strongest result to date in the field of alcoholism and offers a comprehensive—though not exhaustive—window to the genetics and biology of alcoholism."

The study was published in the May 20, 2014, issue of the journal Translational Psychiatry.

Related Links:

Indiana University School of Medicine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.